Response-guided peginterferon therapy for hbeag-positive and hbeag-negative chronic hepatitis b using hepatitis b surface antigen levels: A review

被引：1

作者：

Sonneveld M.J. ^{[1
]}

Brouwer W.P. ^{[1
]}

Janssen H.L.A. ^{[1
,2
,3
,4
,5
]}

机构：

[1] Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam

[2] Toronto Center for Liver Disease, Toronto Western and General Hospital, University Health Network, Toronto

[3] University of Toronto, Toronto

[4] Erasmus University Rotterdam, Rotterdam

[5] Division of Gastroenterology, University Health Network, 399 Bathurst Street, Toronto, M5T 2S8, ON

来源：

Current Hepatology Reports | 2014年 / 13卷 / 3期

关键词：

HBeAg-negative; HBeAg-positive; HBsAg; HBV; Hepatitis B; Hepatitis B surfice antigenemia; PEG-IFN; Peginterferon; Peginterferon therapy;

D O I：

10.1007/s11901-014-0239-1

中图分类号：

学科分类号：

摘要：

Hepatitis B surface antigenemia (HBsAg) is the hallmark of HBV infection. Serum levels of HBsAg appear to reflect the degree of immune control over the virus: lower levels signify a higher level of immune control. One year of peginterferon (PEG-IFN) therapy results in a decline of HBsAg in serum that is sustained off-treatment. Patients who achieve a sustained virological response to PEG-IFN have more pronounced on-treatment HBsAg decline. HBsAg levels during therapy can be used to predict the chance of treatment success. Among HBeAg-positive patients, the probability of response is extremely low in patients with HBsAg levels >20,000 IU/mL at week 24 of treatment and therapy discontinuation is indicated. Similarly, therapy cessation is indicated in HBeAg-negative patients without HBsAg decline at week 12 if HBV DNA has not been reduced by at least 2 log IU/mL. © Springer Science+Business Media New York 2014.

引用

页码：250 / 255

页数：5

共 39 条

[1]

Dienstag J.L., Hepatitis B, virus infection, N Engl J Med, 359, pp. 1486-1500, (2008)

[2]

Rotman Y., Brown T.A., Hoofnagle J.H., Evaluation of the patient with hepatitis B, Hepatology, 49, (2009)

[3]

Sonneveld M.J., Rijckborst V., Boucher C.A., Zwang L., Beersma M.F., Hansen B.E., Et al., A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B, J Clin Virol, 51, pp. 175-178, (2011)

[4]

Jaroszewicz J., Calle Serrano B., Wursthorn K., Deterding K., Schlue J., Raupach R., Et al., Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective, J Hepatol, 52, pp. 514-522, (2010)

[5]

Nguyen T., Thompson A.J., Bowden S., Croagh C., Bell S., Desmond P.V., Et al., Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia, J Hepatol, 52, pp. 508-513, (2010)

[6]

Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., Et al., Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers, Gastroenterology, 139, pp. 483-490, (2010)

[7]

Chan H.L., Wong V.W., Wong G.L., Tse C.H., Chan H.Y., Sung J.J., A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B, Hepatology, 52, pp. 1232-1241, (2010)

[8]

Janssen H.L., Sonneveld M.J., Brunetto M.R., Quantification of serum hepatitis B surface antigen: Is it useful for the management of chronic hepatitis B?, Gut, 61, pp. 641-645, (2012)

[9]

Reijnders J.G., Rijckborst V., Sonneveld M.J., Scherbeijn S.M., Boucher C.A., Hansen B.E., Et al., Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir, J Hepatol, 54, pp. 449-454, (2011)

[10]

Zoutendijk R., Hansen B.E., Van Vuuren A.J., Boucher C.A., Janssen H.L., Serum HBsAg decline during long-term potent nucleos(T)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss, J Infect Dis, 204, pp. 415-418, (2011)

← 1 2 3 4 →